Study to Optimize the Quality of Samples for Cell-mediated Immunity (CMI) in ART-naïve HIV-1-infected Subjects
14 april 2020 uppdaterad av: GlaxoSmithKline
Optimizing the Quality of Samples Used for the Evaluation of Cell-mediated Immune (CMI) Responses in Antiretroviral Therapy (ART)-naïve Human Deficiency Virus Type 1 (HIV-1)-Infected Subjects
The purpose of this study is to investigate a combined set of parameters deemed to impact the quality of CMI analyses in terms of the proportion of viable lymphocytes in antiretroviral therapy-naïve HIV-1 infected subjects.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This study will address the respective and combined impact of (i) timing between blood collection and peripheral blood mononuclear cells (PBMC) processing ["time-to-process"] and (ii) timing of PBMC resting before stimulation ["resting -time"].
Studietyp
Interventionell
Inskrivning (Faktisk)
22
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
-
Gent, Belgien, 9000
- GSK Investigational Site
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år till 55 år (Vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
All subjects must satisfy all the following criteria at study entry:
- Subjects who the Investigator believes can and will comply with the requirements of the protocol.
- Written informed consent obtained from the subject prior to any study procedure.
- A male or female between and including 18 and 55 years of age at the time of enrollment.
- Confirmed HIV-1 infection.
- ART-naïve and not eligible for ART treatment as per established guidelines. Subjects must never have received ART after HIV diagnosis, including lamivudine used for chronic hepatitis B infection. The exception to this is short-term ART for prevention of mother-to-child transmission (PMTCT) which must have been completed at least 360 days prior to enrollment.
- Viral load level between and including 2,000 and 100,000 copies/mL at screening.
- CD4+ T cell count >500 cells/mm3 at screening.
If the subject is female, she must be of non-childbearing potential, i.e., have a current tubal ligation, hysterectomy, ovariectomy or be post-menopausal. Female subjects of childbearing potential may be enrolled in the study, if the subject:
- has practiced adequate contraception for 30 days prior to vaccination, and
- has a negative pregnancy test at screening, and
- has agreed to continue adequate contraception during the entire study period.
Exclusion Criteria:
The following criteria should be checked at the time of study entry. If any exclusion criterion applies, the subject must not be included in the study:
- Infection with HIV-2. This includes subjects with dual infection with HIV-1/HIV-2.
- Planned use of any hematotoxic product during the study period.
- Planned use of any investigational or non-registered product during the study period.
- Acute or chronic, clinically relevant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination, serology and/or medical history at screening.
- Grade 3 or grade 4 laboratory abnormalities, as defined by Division of AIDS (DAIDS) grading table, at screening.
- Any condition which, in the opinion of the Investigator, could compromise the subject's adherence to the study protocol.
- Planned administration of a vaccine not foreseen by the study protocol during the period starting 30 days before the Sample Collection Visit (Visit 2). Vaccine can be administered as after sampling in Visit 2.
- Pregnant or lactating female.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Grundläggande vetenskap
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: HIV-1 Group
Antiretroviral Therapy-naïve HIV1-infected subjects, aged 18 to 55 years, from whom samples for cell-mediated immunity (CMI) were collected.
No investigational vaccine was administered.
|
Blood samples will be collected in all subjects at two time points, at the Screening Visit (Day 0) and at the Sample Collection Visit (Day 15)
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Lymphocytes Viability Prediction (LOGIT Transformed) in CMI Samples Post-overnight Incubation Time Before Intracellular Cytokine Staining (ICS): "Intercept" Parameter Estimate of the Prediction Model - Condition "None" Resting Time Not Included
Tidsram: At Day 15 (sample collection visit)
|
The objective was to model lymphocyte viability according to "time-to-process" (TP=2h, 7h or 24h) and "resting time" (RT=2h, 6h or 18h ["none" resting time not included]) conditions to select the best combination of these two parameters to maximize the post-ICS viability in CMI samples collected from ART-naïve HIV-1-infected subjects.
Viability (%) = 10^P/(1 + 10^P)*100 with P for Prediction.The optimum of the viability was predicted as P (LOGIT)= intercept + a*TP + b*RT + a*b*TP*RT + a*a*TP*TP + b*b*RT*RT.
Where "intercept", "TP", "RT", "TP*RT", "TP *TP", "RT*RT" are the parameters evaluated and presented in the 3 first primary outcomes.
And a and b are log-transformed parameters corresponding respectively to the "TP" and the "RT" where the prediction has to be done.
This outcome is presenting the intercept i.e. expected mean value of Prediction when "TP" and "RT" = 0.
The optimum of this Design of Experiment is presented in outcome 4.
|
At Day 15 (sample collection visit)
|
|
Lymphocytes Viability Prediction (LOGIT Transformed Estimate) in CMI Samples Post-overnight Incubation Time Before ICS: Time to Process and Resting Time Parameter Estimates of the Prediction Model - Condition "None" Resting Time Not Included
Tidsram: At Day 15 (sample collection visit)
|
The objective was to model lymphocyte viability according to "time-to-process" (TP=2h, 7h or 24h) and "resting time" (RT=2h, 6h or 18h ["none" resting time not included]) conditions to select the best combination of these two parameters to maximize the post-ICS viability in CMI samples collected from ART-naïve HIV-1-infected subjects.
Viability (%) = 10 ^ P / (1 + 10 ^ P) * 100 with P for Prediction.The optimum of the viability was predicted as P (LOGIT)= intercept + a*TP + b*RT + a*b*TP*RT + a*a*TP*TP + b*b*RT*RT.
Where "intercept", "TP", "RT", "TP*RT", "TP *TP", "RT*RT" are the parameters evaluated and presented in the 3 first primary outcomes.
And a and b are log-transformed parameters corresponding respectively to the "TP" and the "RT" where the prediction has to be done.
This outcome is presenting "TP" and "RT" estimates expressed as log(hours).
The optimum of this Design of Experiment (DOE) is presented in outcome 4.
|
At Day 15 (sample collection visit)
|
|
Lymphocytes Viability Prediction (LOGIT Transformed Estimate) in CMI Samples Post-overnight Incubation Time Before ICS: TP*RT, TP*TP and RT*RT Parameter Estimates of the Prediction Model - Condition "None" Resting Time Not Included
Tidsram: At Day 15 (sample collection visit)
|
The objective was to model lymphocyte viability according to "time-to-process" (TP=2h, 7h or 24h) and "resting time" (RT=2h, 6h or 18h ["none" resting time not included]) conditions to select the best combination of these two parameters to maximize the post-ICS viability in CMI samples collected from ART-naïve HIV-1-infected subjects.
Viability (%) = 10 ^ P / (1 + 10 ^ P) * 100 with P for Prediction.The optimum of the viability was predicted as P (LOGIT)= intercept + a*TP + b*RT + a*b*TP*RT + a*a*TP*TP + b*b*RT*RT.
Where "intercept", "TP", "RT", "TP*RT", "TP *TP", "RT*RT" are the parameters evaluated and presented in the 3 first primary outcomes.
And a and b are log-transformed parameters corresponding respectively to the "TP" and the "RT" where the prediction has to be done.
This outcome is presenting TP*RT, TP*TP and RT*RT estimates expressed as log(hours^2).
The optimum of this DOE is presented in outcome 4.
|
At Day 15 (sample collection visit)
|
|
Lymphocytes Viability Prediction (LOGIT Transformed Estimate) in CMI Samples Post-overnight Incubation Time Before ICS: Optimum Mean Cell Viability Estimate by the Prediction Model - Condition "None" Resting Time Not Included
Tidsram: At Day 15 (sample collection visit)
|
The objective was to model lymphocyte viability according to "time-to-process" (TP=2h, 7h or 24h) and "resting time" (RT=2h, 6h or 18h ["none" resting time not included]) conditions to select the best combination of these two parameters to maximize the post-ICS viability in CMI samples collected from ART-naïve HIV-1-infected subjects.
Viability (%) = 10 ^ P / (1 + 10 ^ P) * 100 with P for Prediction.The optimum of the viability was predicted as P (LOGIT)= intercept + a*TP + b*RT + a*b*TP*RT + a*a*TP*TP + b*b*RT*RT.
Where "intercept", "TP", "RT", "TP*RT", "TP *TP", "RT*RT" are the parameters evaluated and presented in the 3 first primary outcomes.
And a and b are log-transformed parameters corresponding respectively to the "TP" and the "RT" where the prediction has to be done.
The optimum predicted mean cell viability of this Design of Experiment is presented in this outcome and expressed as percentage.
|
At Day 15 (sample collection visit)
|
|
Lymphocytes Viability Prediction (Non-transformed Estimate) in CMI Samples Post-overnight Incubation Time Before ICS: "Intercept" Parameter Estimate of the Prediction Model - Condition "None" Resting Time Included
Tidsram: At Day 15 (sample collection visit)
|
The objective was to model lymphocyte viability according to "time-to-process" (TP=2h, 7h or 24h) and "resting time" (RT=0h) conditions in order to select the best combination of these two parameters with the aim to maximize the post-ICS viability in CMI samples collected from ART-naïve HIV-1-infected subjects.
Viability (%) = 10 ^ P / (1 + 10 ^ P) * 100 with P for Prediction.
The optimum of the viability was predicted as follows.
P (LOGIT)= intercept + a*TP + b*RT + a*b*TP*RT + + b*b*RT*RT.
Where "intercept", "TP", "RT", "TP*RT", "TP *TP", "RT*RT" are the parameters evaluated and presented in the primary outcomes 5, 6 and 7.
And "a" and "b" are parameters (hour) corresponding respectively to the "TP" and the "RT" where the prediction has to be done.
This outcome is presenting the intercept i.e. expected mean value of Prediction when "TP" and "RT" = 0.
The optimum of this Design of Experiment is presented in outcome 8.
|
At Day 15 (sample collection visit)
|
|
Lymphocytes Viability Prediction (Non-transformed Estimate) in CMI Samples Post-overnight Incubation Time Before ICS: Time to Process and Resting Time Parameter Estimates of the Prediction Model - Condition "None" Resting Time Included
Tidsram: At Day 15 (sample collection visit)
|
The objective was to model lymphocyte viability according to "time-to-process" (TP=2h, 7h or 24h) and "resting time" (RT=0h) conditions in order to select the best combination of these two parameters with the aim to maximize the post-ICS viability in CMI samples collected from ART-naïve HIV-1-infected subjects.
Viability (%) = 10 ^ P / (1 + 10 ^ P) * 100 with P for Prediction.
The optimum of the viability was predicted as follows.
P (LOGIT)= intercept + a*TP + b*RT + a*b*TP*RT + + b*b*RT*RT.
Where "intercept", "TP", "RT", "TP*RT", "TP *TP", "RT*RT" are the parameters evaluated and presented in the primary outcomes 5, 6 and 7.
And "a" and "b" are parameters (hour) corresponding respectively to the "TP" and the "RT" where the prediction has to be done.
This outcome is presenting "TP" and "RT" estimates expressed as log(hours).
The optimum of this Design of Experiment (DOE) is presented in outcome 8.
|
At Day 15 (sample collection visit)
|
|
Lymphocytes Viability Prediction (Non-transformed Estimate) in CMI Samples Post-overnight Incubation Time Before ICS: TP*RT and RT*RT Parameter Estimates of the Prediction Model - Condition "None" Resting Time Included
Tidsram: At Day 15 (sample collection visit)
|
The objective was to model lymphocyte viability according to "time-to-process" (TP=2h, 7h or 24h) and "resting time" (RT=0h) conditions in order to select the best combination of these two parameters with the aim to maximize the post-ICS viability in CMI samples collected from ART-naïve HIV-1-infected subjects.
Viability (%) = 10 ^ P / (1 + 10 ^ P) * 100 with P for Prediction.
The optimum of the viability was predicted as follows.
P (LOGIT)= intercept + a*TP + b*RT + a*b*TP*RT + + b*b*RT*RT.
Where "intercept", "TP", "RT", "TP*RT", "TP *TP", "RT*RT" are the parameters evaluated and presented in the primary outcomes 5, 6 and 7.
And "a" and "b" are parameters (hour) corresponding respectively to the "TP" and the "RT" where the prediction has to be done.
This outcome is presenting TP*RT and RT*RT estimates expressed as log(hours^2).
The optimum of this DOE is presented in outcome 8.
|
At Day 15 (sample collection visit)
|
|
Lymphocytes Viability Prediction (Non-transformed Estimate) in CMI Samples Post-overnight Incubation Time Before ICS: Optimum Mean Cell Viability Estimates by the Prediction Model -Condition "None" Resting Time Included.
Tidsram: At Day 15 (sample collection visit)
|
The objective was to model lymphocyte viability according to "time-to-process" (TP=2h, 7h or 24h) and "resting time" (RT=0h) conditions in order to select the best combination of these two parameters with the aim to maximize the post-ICS viability in CMI samples collected from ART-naïve HIV-1-infected subjects.
Viability (%) = 10 ^ P / (1 + 10 ^ P) * 100 with P for Prediction.
The optimum of the viability was predicted as follows.
P (LOGIT)= intercept + a*TP + b*RT + a*b*TP*RT + + b*b*RT*RT.
Where "intercept", "TP", "RT", "TP*RT", "TP *TP", "RT*RT" are the parameters evaluated and presented in the primary outcomes 5, 6 and 7.
And "a" and "b" are parameters (hour) corresponding respectively to the "TP" and the "RT" where the prediction has to be done.
The optimum predicted mean cell viability of this Design of Experiment is presented in this outcome and expressed as percentage.
|
At Day 15 (sample collection visit)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Percentage of Viable Lymphocytes in the CMI Samples, Post-overnight Incubation (Classic) Before ICS and Post-6 Hour Incubation Before ICS
Tidsram: A Day 15 (sample collection visit)
|
The percentage of viable lymphocytes was determined by Forward Scatter/Side Scatter (FSC/SSC) and LIVE/DEAD gating during flow cytometry analysis for each incubation of time-to-time process (TP) = 2h, 7h and 24 h and resting time (RT) = 18h for the comparison of resting time = 18h and classic incubation time versus resting time = 18h and post-6h incubation time.
|
A Day 15 (sample collection visit)
|
|
Magnitude of HIV-1 RT Specific Cluster of Differentiation 40 Ligand (CD40L+) CD4+ T Cell Responses in the CMI Samples Post-overnight ICS/Post 6 Hour ICS, Expressing at Least One Cytokine
Tidsram: At Day 15 (sample collection visit)
|
Data were collected but could not be reported as data were below level of detection.
|
At Day 15 (sample collection visit)
|
|
Magnitude of HIV-RT Specific (Background Reduced) CD8+ T Cell Responses in the CMI Samples Post-overnight ICS/Post 6 Hour ICS, Expressing at Least One Cytokine
Tidsram: At Day 15 (sample collection visit)
|
HIV-RT specific responses of CD8+ T cells expressing at least one cytokine, among: Interleukin-2 (IL-2), Interferon-gamma (IFN-g) and Tumor necrosis factor alpha (TNF-a),after stimulation with HIV-1 peptide pools for time-to-process (TP) (2, 7, 24 hours) and resting time (RT) (0,2,6,18 hours) post-overnight ICS and for time-to-process (7 hours) and resting time (18 hours) post 6 hours ICS.
|
At Day 15 (sample collection visit)
|
|
Number of Subjects With Serious Adverse Events (SAEs)
Tidsram: During the whole study period (From Day 0 to Day 15)
|
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitali-zation or prolongation of hospitalization or result in disability/incapacity.
|
During the whole study period (From Day 0 to Day 15)
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
25 juni 2012
Primärt slutförande (Faktisk)
30 oktober 2012
Avslutad studie (Faktisk)
30 oktober 2012
Studieregistreringsdatum
Först inskickad
31 maj 2012
Först inskickad som uppfyllde QC-kriterierna
31 maj 2012
Första postat (Uppskatta)
4 juni 2012
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
24 april 2020
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
14 april 2020
Senast verifierad
1 april 2020
Mer information
Termer relaterade till denna studie
Nyckelord
Andra studie-ID-nummer
- 116329
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på AIDS
-
University Hospital, GrenobleSociété Française d'Anesthésie et de RéanimationAvslutadeFast Diagnosis Performance in Guiding First Aid Resuscitation and HemostasisFrankrike
-
Atara BiotherapeuticsRekryteringLymfoproliferativa störningar | Leiomyosarkom | Stamcellstransplantationskomplikationer | Komplikationer vid transplantation av fasta organ | Epstein-Barr-virus (EBV)-associerade sjukdomar | EBV+ post-transplantation lymfoproliferativ sjukdom (EBV+ PTLD) | Allogen hematopoetisk celltransplantation | EBV+ Sarkom och andra villkorFörenta staterna, Österrike, Belgien, Frankrike, Italien, Spanien, Storbritannien
-
Atara BiotherapeuticsInte längre tillgängligLymfoproliferativa störningar | Stamcellstransplantationskomplikationer | Epstein-Barr Virus (EBV) infektioner | EBV+ associerat lymfom | EBV+ associerad post-transplantation lymfoproliferativ sjukdom (EBV+ PTLD) | Epstein-Barr Viremia | Lymfom, AIDS-relaterat | Epstein-Barr-virus-associerad lymfoproliferativ... och andra villkor
Kliniska prövningar på Blood sample collection
-
Hillel Yaffe Medical CenterOkänd
-
OHSU Knight Cancer InstituteOregon Health and Science University; Robert Wood Johnson FoundationAvslutadLivmoderhalscancer | Humant papillomvirusinfektionFörenta staterna
-
Midwest Heart & Vascular SpecialistsRekryteringAL Amyloidos | Amyloid | Hjärtamyloidos | Amyloidos Hjärtat | Systemisk amyloidos | ATTR Amyloidosis Vildtyp | Infiltrativ kardiomyopati, amyloidFörenta staterna
-
Massachusetts General HospitalRekryteringCovid-19Förenta staterna
-
Applied Biology, Inc.IndragenAndrogen alopeci | Håravfall | Håravfall/skallighet | Kvinnligt mönster skallighetFörenta staterna
-
Geneoscopy, Inc.Aktiv, inte rekryterandeKolorektal cancer | Polyp av kolon | Adenom tjocktarm | Avancerat AdenocarcinomFörenta staterna
-
Teal Health, Inc.Aktiv, inte rekryterandeMänskligt papillomvirus | Humant papillomvirusinfektion typ 16 | Humant papillomvirusinfektion typ 18Förenta staterna
-
IdentigeneCRI Lifetree Clinical ResearchOkänd
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)RekryteringLivmoderhalscancer | Humant papillomvirusinfektionFörenta staterna